Shares of French pharmaceutical giant Sanofi SA (SNY) soared 5.06% intraday on Thursday, following the company's impressive fourth-quarter results and positive guidance for 2025, coupled with a planned share buyback program.

Sanofi reported a 10.3% increase in Q4 sales at constant exchange rates, fueled by robust performances from key products like Dupixent, the blockbuster asthma drug, and Beyfortus, a newly launched vaccine for infants. While business operating income dipped 7.7%, it aligned with analyst expectations.

For the full year 2024, Sanofi exceeded its business EPS guidance, driven by an 11.3% sales growth at constant exchange rates. The company's pipeline also showed progress, with 14 regulatory approvals and 21 submission acceptances for new medicines and vaccines.

Looking ahead to 2025, Sanofi forecasts mid-to-high single-digit sales growth and a strong rebound in business EPS, with low double-digit percentage growth expected before the impact of share buybacks. The company plans to repurchase €5 billion worth of shares in 2025, boosting investor confidence.